Icahn School of Medicine at Mount Sinai

University of Kansas

John Cijiang He

Bhaskar C Das

Barbara Murphy

Zhengzhe Li

Ruijie Liu

Kyung Lee

Wenzhen Xiao

Bhaskar Das

A method for identifying the risk of developing Chronic Allograft Nephropathy (CAN) in a patient that received a kidney transplant from a donor which comprises identifying the race of the donor; determining the levels of SHROOM 3 expression in a kidney biopsy specimen obtained from the patient at a predetermined time after transplant; comparing the level of SHROOM 3 expression in the biopsy specimen with the levels of SHROOM 3 expression in a control; determining if the level of SHROOM 3 expression in the allograft is significantly higher than in the control, and diagnosing the patient as being at risk for CAN if the level of SHROOM 3 expression in the specimen is significantly higher than in the control.

Use of SHROOM3 in chronic kidney disease and chronic allograft nephropathy

Compounds that are selective inhibitors of Smad3 activation are disclosed. The compounds have the following structure: in which Z is an oxadiazole. The compounds disclosed are useful in treatment of fibrotic disease, particularly renal fibrosis, and similar diseases associated with the dysregulation of the HIPK2/Smad3 signaling pathway.

Oxadiazole inhibitors of HIPK2 for treating kidney fibrosis

Growing community of inventors

New York, NY, United States of America

John Cijiang He